Medication utilization for patients with chronic rhinosinusitis with nasal polyposis and asthma in 12 months pre- and post-dupilumab initiation

Int Forum Allergy Rhinol. 2024 Aug;14(8):1399-1401. doi: 10.1002/alr.23340. Epub 2024 Feb 26.

Abstract

This study examines the impact of dupilumab on medication use for chronic rhinosinusitis with nasal polyposis (CRSwNP) and asthma patients. Patients on dupilumab had a reduction in oral/inhaled/topical steroids, antibiotics, and leukotriene receptor antagonists (LTRAs). The reduction in medication use had no impact on total polyp or SNOT-22 scores.

Keywords: asthma; chronic rhinosinusitis; quality of life; steroid therapy.

MeSH terms

  • Anti-Bacterial Agents / administration & dosage
  • Anti-Bacterial Agents / therapeutic use
  • Antibodies, Monoclonal, Humanized* / administration & dosage
  • Antibodies, Monoclonal, Humanized* / therapeutic use
  • Asthma* / drug therapy
  • Chronic Disease
  • Humans
  • Leukotriene Antagonists / administration & dosage
  • Leukotriene Antagonists / therapeutic use
  • Nasal Polyps* / drug therapy
  • Rhinosinusitis* / drug therapy

Substances

  • Anti-Bacterial Agents
  • Antibodies, Monoclonal, Humanized
  • dupilumab
  • Leukotriene Antagonists